233 related articles for article (PubMed ID: 28576889)
1. Blood coagulation system in patients with chronic kidney disease: a prospective observational study.
Huang MJ; Wei RB; Wang Y; Su TY; Di P; Li QP; Yang X; Li P; Chen XM
BMJ Open; 2017 Jun; 7(5):e014294. PubMed ID: 28576889
[TBL] [Abstract][Full Text] [Related]
2. Activation of endothelium, coagulation and fibrinolysis is enhanced and associates with renal anti-neutrophil cytoplasmic antibody-associated vasculitis.
Salmela A; Ekstrand A; Joutsi-Korhonen L; Räisänen-Sokolowski A; Lassila R
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i53-9. PubMed ID: 25523447
[TBL] [Abstract][Full Text] [Related]
3. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.
Ågren A; Holmström M; Schmidt DE; Hosokawa K; Blombäck M; Hjemdahl P
Thromb Haemost; 2017 Jan; 117(1):75-85. PubMed ID: 27761577
[TBL] [Abstract][Full Text] [Related]
5. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor.
Rietveld IM; Lijfering WM; le Cessie S; Bos MHA; Rosendaal FR; Reitsma PH; Cannegieter SC
J Thromb Haemost; 2019 Jan; 17(1):99-109. PubMed ID: 30471183
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
7. Impact of aerobic exercise on haemostatic indices in paediatric patients with haemophilia.
Kumar R; Bouskill V; Schneiderman JE; Pluthero FG; Kahr WH; Craik A; Clark D; Whitney K; Zhang C; Rand ML; Carcao M
Thromb Haemost; 2016 Jun; 115(6):1120-8. PubMed ID: 26917411
[TBL] [Abstract][Full Text] [Related]
8. Decreased von Willebrand factor ristocetin cofactor activity and increased ADAMTS13 antigen increase postoperative drainage after coronary artery bypass grafting.
Mazur P; Plicner D; Zdziarska J; Sadowski J; Undas A
Eur J Cardiothorac Surg; 2014 Feb; 45(2):e26-32. PubMed ID: 24351199
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers.
Tauber H; Ott H; Streif W; Weigel G; Loacker L; Fritz J; Heinz A; Velik-Salchner C
Anesth Analg; 2015 Apr; 120(4):730-6. PubMed ID: 25565317
[TBL] [Abstract][Full Text] [Related]
11. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
Stufano F; Lawrie AS; La Marca S; Berbenni C; Baronciani L; Peyvandi F
Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
[TBL] [Abstract][Full Text] [Related]
14. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
[TBL] [Abstract][Full Text] [Related]
15. Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance.
de Maistre E; Volot F; Mourey G; Aho LS; Ternisien C; Briquel ME; Bertrand MA; Tardy B; Frotscher B; Nguyen P; Dumont L; Vandroux D; Hézard N; Trossaërt M
Thromb Haemost; 2014 Oct; 112(4):825-30. PubMed ID: 25103956
[TBL] [Abstract][Full Text] [Related]
16. Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes.
Tobin WO; Kinsella JA; Kavanagh GF; O'Donnell JS; McGrath RT; Tierney S; Egan B; Feeley TM; Coughlan T; Collins DR; O'Neill D; Murphy S; Lim SJ; Murphy RP; McCabe D
J Neurol Sci; 2017 Apr; 375():404-410. PubMed ID: 28320178
[TBL] [Abstract][Full Text] [Related]
17. Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.
Hillarp A; Friedman KD; Adcock-Funk D; Tiefenbacher S; Nichols WL; Chen D; Stadler M; Schwartz BA
Haemophilia; 2015 Nov; 21(6):837-45. PubMed ID: 26172561
[TBL] [Abstract][Full Text] [Related]
18. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
19. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19.
Rauch A; Labreuche J; Lassalle F; Goutay J; Caplan M; Charbonnier L; Rohn A; Jeanpierre E; Dupont A; Duhamel A; Faure K; Lambert M; Kipnis E; Garrigue D; Lenting PJ; Poissy J; Susen S
J Thromb Haemost; 2020 Nov; 18(11):2942-2953. PubMed ID: 32881304
[TBL] [Abstract][Full Text] [Related]
20. Platelet ligands and ADAMTS13 during Puumala hantavirus infection and associated thrombocytopenia.
Laine O; Mäkelä S; Mustonen J; Helminen M; Vaheri A; Lassila R; Joutsi-Korhonen L
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):468-72. PubMed ID: 21508829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
